Comparison of Tumor Regression Rate in Cervical Cancer Patients Treated with Radiotherapy Alone versus Chemoradiotherapy

Aim: The aim of the research was to compare the tumor regression rate between Cervical Cancerpatients treated with radiation therapy alone or concurrent chemo-radiotherapy. Patients and methods: Seventy-two patients with IIA-IIIB stage cervical cancer were included.Patients were divided to 2 groups. In group I, we used EBRT in total dose of 46-50 Gy andHDR ICBT – two divided doses of 9,0 Gy weekly. In group II, we carried out the sameradiotherapy regimen with additionally cisplatin (40 mg/m2, weekly, 5 weeks). The longestdiameter of the tumor before treatment was compared to measurement after EBRT but prior toICBT. Treatment response rate was evaluated 1 month after end of the treatment.Results: Tumor regression prior to ICBT varied widely, ranging from 12% to 61%. However,the tumor regression rate was higher in patients treated with chemo-radiotherapy, ranging from39% to 61% (Mean 53%) compared to radiotherapy alone ranging from 12% to 49% (Mean35%). In tumors with longest diameter ≥5 cm, tumor regression rate was ranged between 12%to 42% (median 26,2%) in patients treated with radiotherapy alone, and between 39% to 48%(median 44,8%) in patients treated with chemoradiotherapy. Conclusions: Outcome of this study for advanced cervical cancer treated by EBRT,brachytherapy and simultaneous chemotherapy shows satisfactory tumor shrinkage rate amongall patients. Our results show that tumor regression rate is significantly higher in patients treatedwith concurrent chemoradiotherapy compared to radiotherapy alone.